Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3M Aldara submission

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

3M submits sNDA for use of its topical immune response modifier Aldara (imiquimod cream, 5%) for superficial basal cell carcinoma. The submission is based on two six-week, double-blind, placebo-controlled studies in 724 patients. The studies found dosing five times a week to be the optimal regimen, with a histological clearance rate of 82% vs. 3% for placebo. Aldara could also be cleared for another indication in 2004; 3M submitted an sNDA May 5 for actinic keratosis (1Pharmaceutical Approvals Monthly June 1, 2003, p. 15)...
Advertisement

Related Content

3M Submits Aldara For Actinic Keratosis, Plans Carcinoma Filing Mid-Year

Topics

Advertisement
UsernamePublicRestriction

Register

PS002285

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel